Zevra therapeutics to present top-line data from the phase 2 clinical trial of kp1077 for idiopathic hypersomnia at sleep europe 2024

Kp1077 demonstrates clinically meaningful benefits for key ih symptoms top-line data provide key information for the design of a phase 3 study celebration, fla., sept. 24, 2024 (globe newswire) -- zevra therapeutics, inc. (nasdaqgs: zvra) (zevra, or the company) a commercial-stage rare disease therapeutics company, today announced that rene braeckman, ph.d.
ZVRA Ratings Summary
ZVRA Quant Ranking